Provided by Tiger Trade Technology Pte. Ltd.

MannKind

2.47
-0.0500-1.98%
Post-market: 2.500.0256+1.04%19:43 EDT
Volume:19.09M
Turnover:47.27M
Market Cap:758.46M
PE:123.50
High:2.54
Open:2.54
Low:2.41
Close:2.52
52wk High:6.51
52wk Low:2.41
Shares:307.07M
Float Shares:300.98M
Volume Ratio:4.29
T/O Rate:6.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0200
EPS(LYR):0.0200
ROE:32.74%
ROA:4.91%
PB:-14.87
PE(LYR):123.50

Loading ...

Wedbush Cuts Price Target on MannKind to $10 From $11, Keeps Outperform Rating

MT Newswires Live
·
Nov 11, 2025

MannKind’s Strategic Advancements and Product Potential Justify Buy Rating Despite MNKD-101 Discontinuation

TIPRANKS
·
Nov 11, 2025

REFILE-BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Tower Semiconductor, GlobalFoundries

Reuters
·
Nov 11, 2025

H.C. Wainwright remains bullish on MannKind despite disappointing MNKD-101 news

TIPRANKS
·
Nov 11, 2025

MannKind’s Resilience and Growth Potential: A Buy Rating Amid Setbacks and Opportunities

TIPRANKS
·
Nov 11, 2025

MannKind Corp : Leerink Partners Cuts Target Price to $7 From $9

THOMSON REUTERS
·
Nov 10, 2025

MannKind Shares Fall 3.3% After Co to Discontinue Late-Stage Trial of Lung Disease Treatment

THOMSON REUTERS
·
Nov 10, 2025

MannKind Discontinues Phase 3 Trial of Nebulized Clofazimine to Treat Lung Disease

MT Newswires Live
·
Nov 10, 2025

MannKind Shares Down After Lung Disease Drug Trial Discontinued

Dow Jones
·
Nov 10, 2025

MannKind provides update on Phase 3 ICoN-1 trial of nebulized clofazimine

TIPRANKS
·
Nov 10, 2025

MannKind Shares Fall 5.7% Premarket After Co to Discontinue Phase 3 Clinical Trial of Lung Disease Treatment

THOMSON REUTERS
·
Nov 10, 2025

Stock Track | MannKind Plunges 6.75% Pre-market as Company Discontinues Key Phase 3 Trial

Stock Track
·
Nov 10, 2025

Stock Track | MannKind Shares Plummet 6.75% Pre-market on Discontinuation of Key Phase 3 Trial

Stock Track
·
Nov 10, 2025

MannKind Corp - Mnkd-102 Development Remains Under Consideration

THOMSON REUTERS
·
Nov 10, 2025

MannKind: No Conversions Observed in Phase 3 ICON-1 Trial, Prompting Concerns Regarding Likelihood of Achieving Study's Key Primary Endpoint

THOMSON REUTERS
·
Nov 10, 2025

MannKind Provides Update on Phase 3 ICON-1 Trial of Nebulized Clofazimine for Ntm Lung Disease

THOMSON REUTERS
·
Nov 10, 2025

MannKind Corp - Independent Dsmb Agrees to Discontinue Trial Due to Futility

THOMSON REUTERS
·
Nov 10, 2025

MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

GlobeNewswire
·
Nov 06, 2025

MannKind’s Record Q3 2025 Earnings and Strategic Moves

TIPRANKS
·
Nov 06, 2025

Update: MannKind Shares Rise After Q3 Beat

MT Newswires Live
·
Nov 06, 2025